Merck's Q4 2013 earnings call shows a company managing through generic erosion, significant forex impact, and guiding for a lower full-year EPS due to these headwinds. However, management expressed confidence in their pipeline, particularly with the advancement of MK3475 in oncology, and aggressive cost management, aiming for future growth. Despite a trough year anticipated for 2014 earnings, the strategic initiatives on cost savings and pipeline development should support the stock over the next 1â€“2 weeks, with investors likely to view these positive steps towards efficiency and promising pipeline candidates favorably.
[0]